Page 178 - 2026 SMOG

VECURONIUM (NORCURON)
Class/Mechanism of Action
• Nondepolarizing Neuromuscular Blocking Agent (Paralytic)
Blocks acetylcholine from binding to motor neuron receptors, inhibiting depolarization.
˚ Onset of action—IV: 2–5min; Duration—IV: approximately 35–65min
Indications
• Labeled Indications
˚ Rapid sequence intubation and neuromuscular blockade
Contraindications
• Hypersensitivity to vecuronium or any component of the formulation
Adverse Reactions/Precautions
• Resistance may occur in burn patients (>30% of body) for a period of 5–70 days after injury.
• High potential for interactions: Numerous drugs either antagonize (e.g., acetylcholinesterase
inhibitors) or potentiate (e.g., calcium channel blockers, certain antimicrobials, inhalation
anesthetics, lithium, magnesium salts, procainamide, and quinidine) the effects of
neuromuscular blockade; use with caution in patients receiving these agents
• Provides NO analgesia or sedation! Must provide appropriate sedation and analgesia prior to
paralytic use and throughout maintenance
• Pregnancy: Use with caution
• Lactation: Unknown
Dose/Administration
PEDIATRIC
ADULT
(Always reference Broselow Tape)
RSI and Maintenance of Paralysis RSI and Maintenance of Paralysis
• IV Push • IV Push
˚ Induction: 0.1mg/kg ˚ Induction: 0.1mg/kg
(dose range: 0.08–0.1mg/kg/dose)
(dose range: 0.08–0.1mg/kg)
q30–60min prn

170 • MEDICATIONS